aripiprazole has been researched along with Lewy Body Disease in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lee, C; Shen, YC | 1 |
Fujishiro, H; Iwamoto, K; Ozaki, N | 1 |
Schwankhaus, J; Singh, S | 1 |
Hurtig, HI; Weintraub, D | 1 |
1 review(s) available for aripiprazole and Lewy Body Disease
Article | Year |
---|---|
Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Cholinesterase Inhibitors; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Humans; Lewy Body Disease; Male; Parkinson Disease; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones | 2007 |
3 other study(ies) available for aripiprazole and Lewy Body Disease
Article | Year |
---|---|
Aripiprazole Improves Psychotic, Cognitive, and Motor Symptoms in a Patient With Lewy Body Dementia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Cognitive Dysfunction; Humans; Lewy Body Disease; Male; Psychotic Disorders; Tremor | 2017 |
Effect of aripiprazole augmentation for depressive symptoms changes with progression of Lewy body disease.
Topics: Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Disease Progression; Drug Synergism; Female; Humans; Lewy Body Disease | 2017 |
Olfactory disturbance in Parkinson disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Biomarkers; Brain; Cognition Disorders; Constipation; Diagnosis, Differential; Disease Progression; Electroencephalography; Hallucinations; Humans; Levetiracetam; Lewy Body Disease; Male; Olfactory Pathways; Parkinson Disease; Piperazines; Piracetam; Quinolones; REM Sleep Behavior Disorder; Treatment Failure; Tremor | 2009 |